Chitosan-Based Nanoparticulates for Oral Delivery of Biopharmaceuticals

Chitosan-Based Systems for Biopharmaceuticals: Delivery, Targeting and Polymer Therapeutics

Volumn , Issue , 2012, Pages 225-241

  Antunes, Filipa ^a   Andrade, Fernanda ^a   Sarmento, Bruno ^a,b  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSITY INSTITUTE OF HEALTH SCIENCES IUCS   (Portugal)

Author keywords

And clinically relevant oral bioavailability; Biopharmaceutical drugs; Cationic polymers; Chitosan; Chitosan role in biopharmaceutical protection; Chitosan based nanoparticles for oral delivery; Chitosan based nanoparticulates; Chitosans; Gene therapy; Hindered by high MW; Iin replacing defective genes; In oral delivery; Major challenge in terms of formulation; Oral absorption of biopharmaceuticals; PEI; Perfectly mastered; poly(L lysine); Protecting genetic material from GI; Technology of chitosan based nanosystems

Indexed keywords

EID: 84885517915     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781119962977.ch13     Document Type: Chapter

References (101)

1. Devalapally, H., Chakilam, A. and Amiji, M.M. (2007) Role of nanotechnology in pharmaceutical product development. J. Pharm. Sci., 96, 2547-2565.
2. Bernkop-Schnürch, A. (2000) Chitosan and its derivatives: potential excipients for peroral peptide delivery systems. Int. J. Pharm., 194, 1-13.
3. Cano-Cebrian, M.J., Zornoza, T., Granero, L. and Polache, A. (2005) Intestinal absorption enhancement via the paracellular route by fatty acids, chitosans and others: a target for drug delivery. Curr. Drug Deliv., 2, 9-22.
4. Park, K., Kwon, I.C. and Park, K. (2011) Oral protein delivery: current status and future prospect. React. Funct. Polym., 71, 280-287.
5. Soderquist, R.G., Milligan, E.D., Sloane, E.M. et al. (2009) PEGylation of brain-derived neurotrophic factor for preserved biological activity and enhanced spinal cord distribution. J. Biomed. Mater. Res. A, 91, 719-729.
6. Brown, L.R. (2005) Commercial challenges of protein drug delivery. Expert Opin. Drug Deliv., 2, 29-42.
7. Mahato, R., Narang, A., Thoma, L. and Miller, D. (2003) Emerging trends in oral delivery of peptide and protein drugs. Crit. Rev. Ther. Drug Carrier Syst., 20, 153-214.
8. Hamman, J.H., Enslin, G.M. and KotŹe, A.F. (2005) Oral delivery of peptide drugs: barriers and developments. Biodrugs, 19, 165-177.
9. Bernkop-Schnürch, A. and Schmitz, T. (2007) Presystemic metabolism of orally administered peptide drugs and strategies to overcome it. Curr. Drug Metab., 8, 509-517.
10. Sonaje, K., Lin, K.-J.,Wang, J.-J. et al. (2010) Self-assembled pH-sensitive nanoparticles: a platform for oral delivery of protein drugs. Adv. Funct. Mater., 20, 3695-3700.
11. Díaz, A., David, A., Pérez, R. et al. (2010) Nanoencapsulation of insulin into zirconium phosphate for oral delivery applications. Biomacromolecules, 11, 2465-2470.
12. Mohanraj, V.J., Barnes, T.J. and Prestidge, C.A. (2010) Silica nanoparticle coated liposomes: a new type of hybrid nanocapsule for proteins. Int. J. Pharm., 392, 285-293.
13. Sajeesh, S., Vauthier, C., Gueutin, C. et al. (2010) Thiol functionalized polymethacrylic acid-based hydrogel microparticles for oral insulin delivery. Acta Biomater., 6, 3072-3080.
14. Cheng,W.-P., Thompson, C., Ryan, S.M. et al. (2010) In vitro and in vivo characterisation of a novel peptide delivery system: amphiphilic polyelectrolyte-salmon calcitonin nanocomplexes. J. Control. Release, 147, 289-297.
15. Cavazzana-Calvo, M., Hacein-Bey, S., de Saint Basile, G. et al. (2000) Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science, 288, 669-672.
16. Meyer, M., Rao, G., Ren, K. and Hughes, J. (2006) Pharmacokinetics of viral and non-viral gene delivery vectors, in Pharmacokinetics and Pharmacodynamics of Biotech Drug-Principles and Case Studies in Drug Development (ed B. Meibohm), Wiley-VCH, Weinheim.
17. Rubanyi, G.M. (2007) Gene therapy-basic principles and the road from bench to bedside, in Handbook of Pharmaceutical Biotechnology (ed S.C. Gad), John Wiley, Hoboken, NJ.
18. Pouton, C. and Seymour, L. (2001) Key issues in non-viral gene delivery. Adv. Drug Deliv. Rev., 46, 187-203.
19. Pascolo, S. (2007) Plasmid DNA and messenger RNA for therapy, in Handbook of Pharmaceutical Biotechnology (ed S.C. Gad) John Wiley, Hoboken, NJ.
20. Polyak, S., Mah, C., Porvasnik, S. et al. (2008) Gene delivery to intestinal epithelial cells in vitro and in vivo with recombinant adeno-associated virus types 1, 2 and 5. Dig. Dis. Sci., 53, 1261-1270.
21. Guimarães, V., Innocentin, S., Chatel, J.M. et al. (2009) A new plasmid vector for DNA delivery using lactococci. Genet. Vaccines Ther., 7, 4.
22. Garrait, G., Jarrige, J.F., Blanquet-Diot, S. and Alric, M. (2009) Genetically engineered yeasts as a new delivery vehicle of active compounds to the digestive tract: in vivo validation of the concept in the rat. Metab. Eng., 11, 148-154.
23. Logue, C.H., Phillips, A.T., Mossel, E.C. et al. (2010) Treatment with cationic liposome-DNA complexes (CLDCs) protects mice from lethal Western equine encephalitis virus (WEEV) challenge. Antiviral Res., 87, 195-203.
24. Kawase, M., Hayashi,Y., Kinoshita, F. et al. (2004) Protective effect of montmorillonite on plasmidDNAin oral gene delivery into small intestine. Biol. Pharm. Bull., 27, 2049-2051.
25. Bhavsar, M.D. and Amiji, M.M. (2008) Development of novel biodegradable polymeric nanoparticles-in-microsphere formulation for local plasmid DNA delivery in the gastrointestinal tract. AAPS PharmSciTech, 9, 288-294.
26. Segura, T. (2007) Formulations and delivery limitations of nucleic-acid-based therapies, in Handbook of Pharmaceutical Biotechnology (ed S.C. Gad), John Wiley, Hoboken, NJ.
27. Mao, S., Sun,W. and Kissel,T. (2010) Chitosan-based formulations for delivery ofDNAand siRNA. Adv. Drug Deliv. Rev., 62, 12-27.
28. Houk, B., Martin, R., Hochhaus, G. and Hughes, J. (2001) Pharmacokinetics of plasmidDNAin the rat. Pharm. Res., 18, 67-74.
29. Houk, B., Hochhaus, G. and Hughes, J. (1999) Kinetic modeling of plasmid DNA degradation in rat plasma. AAPS PharmSci, 1, E9.
30. Rudzinski,W.E. and Aminabhavi, T.M. (2010) Chitosan as a carrier for targeted delivery of small interfering RNA. Int. J. Pharm., 399, 1-11.
31. Page, D. and Cudmore, S. (2001) Innovations in oral gene delivery: challenges and potentials. Drug Discov. Today, 6, 92-101.
32. Fasano, A. (1998) Novel approaches for oral delivery of macromolecules. J. Pharm. Sci., 87, 1351-1356.
33. Bowman, K. and Leong, K.W. (2006) Chitosan nanoparticles for oral drug and gene delivery. Int. J. Nanomedicine, 1, 117-128.
34. Martien, R. (2009) Oral delivery of nucleic acid drugs, in Oral Delivery of Macromolecular Drugs-Barriers, Strategies and Future Trends (ed A. Bernkop-Schnürch), Springer, New York.
35. Bernkop-Schnürch, A. and Clausen, A. (2002) Biomembrane permeability of peptides: strategies to improve their mucosal uptake. Mini Rev. Med. Chem., 2, 295-305.
36. Lai, S.,Wang,Y. and Hanes, J. (2009) Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv. Drug Deliv. Rev., 61, 158-171.
37. Oliveira, S., HØgset, A., Storm, G. and Schiffelers, R.M. (2008) Delivery of siRNA to the target cell cytoplasm: photochemical internalization facilitates endosomal escape and improves silencing efficiency, in vitro and in vivo. Curr. Pharm. Des., 14, 3686-3697.
38. Walther, W., Stein, U., Siegel, R. et al. (2005) Use of the nuclease inhibitor aurintricarboxylic acid (ATA) for improved non-viral intratumoral in vivo gene transfer by jet-injection. J. Gene Med., 7, 477-485.
39. Ross, G.F., Bruno, M.D., Uyeda, M. et al. (1998) Enhanced reporter gene expression in cells transfected in the presence of DMI-2, an acid nuclease inhibitor. Gene Ther., 5, 1244-1250.
40. Sperinde, J.J., Choi, S.J. and Szoka, F.C. (2001) Phage display selection of a peptide DNase II inhibitor that enhances gene delivery. J. Gene Med., 3, 101-108.
41. Amidi, M., Mastrobattista, E., Jiskoot, W. and Hennink, W. (2010) Chitosan-based delivery systems for protein therapeutics and antigens. Adv. Drug Deliv. Rev., 62, 59-82.
42. Morishita, M. and Peppas, N. (2006) Is the oral route possible for peptide and protein drug delivery? Drug Discov. Today, 11, 905-910.
43. Salamat-Miller, N. and Johnston, T. (2005) Current strategies used to enhance the paracellular transport of therapeutic polypeptides across the intestinal epithelium. Int. J. Pharm., 294, 201-216.
44. MacLaughlin, F., Mumper, R.,Wang, J. et al. (1998) Chitosan and depolymerized chitosan oligomers as condensing carriers for in vivo plasmid delivery. J. Control. Release, 56, 259-272.
45. Plapied, L., Vandermeulen, G., Vroman, B. et al. (2010) Bioadhesive nanoparticles of fungal chitosan for oral DNA delivery. Int. J. Pharm., 398, 210-218.
46. Cefalu, W. (2004) Concept, strategies, and feasibility of noninvasive insulin delivery. Diabetes Care, 27, 239-246.
47. Sarmento, B., Ribeiro, A., Veiga, F. et al. (2007) Alginate/chitosan nanoparticles are effective for oral insulin delivery. Pharm. Res., 24, 2198-2206.
48. Sarmento, B., Ribeiro, A., Veiga, F. et al. (2007) Oral bioavailability of insulin contained in polysaccharide nanoparticles. Biomacromolecules, 8, 3054-3060.
49. Wei,W., Ma, G.H.,Wang, L.Y. et al. (2010) Hollowquaternized chitosan microspheres increase the therapeutic effect of orally administered insulin. Acta Biomater., 6, 205-209.
50. Sarmento, B., Ribeiro, A., Veiga, F. and Ferreira, D. (2006) Development and characterization of new insulin containing polysaccharide nanoparticles. Colloids Surf. B Biointerfaces, 53, 193-202.
51. Sarmento, B., Ribeiro, A.J., Veiga, F. et al. (2007) Insulin-loaded nanoparticles are prepared by alginate ionotropic pre-gelation followed by chitosan polyelectrolyte complexation. J. Nanosci. Nanotechnol., 7, 2833-2841.
52. Sarmento, B., Ferreira, D., Jorgensen, L. and van de Weert, M. (2007) Probing insulin's secondary structure after entrapment into alginate/chitosan nanoparticles. Eur. J. Pharm. Biopharm., 65, 10-17.
53. Zhang,Y.,Wei,W., Lv, P. et al. (2011) Preparation and evaluation of alginate-chitosan microspheres for oral delivery of insulin. Eur. J. Pharm. Biopharm, 77, 11-19.
54. Kai, E. and Ochiya, T. (2004)Amethod for oralDNAdelivery with N-acetylated chitosan. Pharm. Res., 21, 838-843.
55. Yuan, Y., Tan, J.,Wang, Y. et al. (2009) Chitosan nanoparticles as non-viral gene delivery vehicles based on atomic force microscopy study. Acta Biochim. Biophys. Sin., 41, 515-526.
56. Chen, J., Yang,W.L., Li, G. et al. (2004) Transfection of mEpo gene to intestinal epithelium in vivo mediated by oral delivery of chitosan-DNA nanoparticles. World J. Gastroenterol., 10, 112-116.
57. Huang, M., Fong, C.W., Khor, E. and Lim, L.Y. (2005) Transfection efficiency of chitosan vectors: effect of polymer molecular weight and degree of deacetylation. J Control Release, 106, 391-406.
58. Chae, S.Y., Son, S., Lee, M. et al. (2005) Deoxycholic acid-conjugated chitosan oligosaccharide nanoparticles for efficient gene carrier. J. Control. Release, 109, 330-344.
59. Richardson, S.C., Kolbe, H.V. and Duncan, R. (1999) Potential of low molecular mass chitosan as a DNA delivery system: biocompatibility, body distribution and ability to complex and protect DNA. Int. J. Pharm., 178, 231-243.
60. Strand, S.P., Lelu, S., Reitan, N.K. et al. (2010) Molecular design of chitosan gene delivery systems with an optimized balance between polyplex stability and polyplex unpacking. Biomaterials, 31, 975-987.
61. Loretz, B., Föger, F.,Werle, M. and Bernkop-Schnürch, A. (2006) Oral gene delivery: strategies to improve stability of pDNA towards intestinal digestion. J. Drug Target., 14, 311-319.
62. Martien, R., Loretz, B. and Schnürch, A.B. (2006) Oral gene delivery: design of polymeric carrier systems shielding toward intestinal enzymatic attack. Biopolymers, 83, 327-336.
63. Ishii, T., Okahata, Y. and Sato, T. (2001) Mechanism of cell transfection with plasmid/chitosan complexes. Biochim. Biophys. Acta, 1514, 51-64.
64. Lai, W.F. and Lin, M.C. (2009) Nucleic acid delivery with chitosan and its derivatives. J. Control. Release, 134, 158-168.
65. Fattal, E. and Vauthier, C. (2007) Drug delivery: nanoparticles, in Encyclopedia of Pharmaceutical Technology, 3rd edn, vol. 1 (ed J. Swarbrick), Informa Healthcare, New York.
66. Hussain, N., Jaitley, V. and Florence, A.T. (2001) Recent advances in the understanding of uptake of microparticulates across the gastrointestinal lymphatics. Adv. Drug Deliv. Rev., 50, 107-142.
67. Vllasaliu, D., Exposito-Harris, R., Heras, A. et al. (2010) Tight junction modulation by chitosan nanoparticles: comparison with chitosan solution. Int. J. Pharm., 400, 183-193.
68. Huang, L., Xin, J., Guo, Y. and Li, J. (2010) A novel insulin oral delivery system assisted by cationic betacyclodextrin polymers. J. Appl. Polym. Sci., 115, 1371-1379.
69. Anitha, A., Deepa, N., Chennazhi, K. et al. (2011) Development of mucoadhesive thiolated chitosan nanoparticles for biomedical applications. Carbohydr. Polym., 83, 66-73.
70. Ma, Z., Lim, T. and Lim, L. (2005) Pharmacological activity of peroral chitosan-insulin nanoparticles in diabetic rats. Int. J. Pharm., 293, 271-280.
71. Jintapattanakit, A., Junyaprasert, V.B., Mao, S. et al. (2007) Peroral delivery of insulin using chitosan derivatives: a comparative study of polyelectrolyte nanocomplexes and nanoparticles. Int. J. Pharm., 342, 240-249.
72. Xu, Y. and Du, Y. (2003) Effect of molecular structure of chitosan on protein delivery properties of chitosan nanoparticles. Int. J. Pharm., 250, 215-226.
73. Calvo, P., Ramunñán-Lopez, C., Jato, J.L.V. and Alonso, M.J. (1997) Novel hydrophilic chitosan-polyethylene oxide nanoparticles as protein carriers. J. Appl. Polym. Sci., 63, 125-132.
74. Janes, K.A., Calvo, P. and Alonso, M.J. (2001) Polysaccharide colloidal particles as delivery systems for macromolecules. Adv. Drug Deliv. Rev., 47, 83-97.
75. Trapani, A., Lopedota, A., Franco, M. et al. (2010) A comparative study of chitosan and chitosan/cyclodextrin nanoparticles as potential carriers for the oral delivery of small peptides. Eur. J. Pharm. Biopharm., 75, 26-32.
76. Zhang, N., Li, J., Jiang, W. et al. (2010) Effective protection and controlled release of insulin by cationic [beta]- cyclodextrin polymers from alginate/chitosan nanoparticles. Int. J. Pharm., 393, 213-219.
77. Werle, M., Takeuchi, H. and Bernkop-Schnürch, A. (2009) Modified chitosans for oral drug delivery. J. Pharm. Sci., 98, 1643-1656.
78. Prego, C., Torres, D., Fernandez-Megia, E. et al. (2006) Chitosan-PEG nanocapsules as new carriers for oral peptide delivery: effect of chitosan pegylation degree. J. Control. Release, 111, 299-308.
79. Sandri, G., Bonferoni, M., Rossi, S. et al. (2007) Nanoparticles based on N-trimethylchitosan: evaluation of absorption properties using in vitro (Caco-2 cells) and ex vivo (excised rat jejunum) models. Eur. J. Pharm. Biopharm., 65, 68-77.
80. Sandri, G., Bonferoni, M.C., Rossi, S. et al. (2010) Insulin-loaded nanoparticles based on N-trimethyl chitosan: in vitro (Caco-2 model) and ex vivo (excised rat jejunum, duodenum, and ileum) evaluation of penetration enhancement properties. AAPS PharmSciTech, 11, 362-371.
81. Yin, L., Ding, J., He, C. et al. (2009) Drug permeability and mucoadhesion properties of thiolated trimethyl chitosan nanoparticles in oral insulin delivery. Biomaterials, 30, 5691-5700.
82. Shelma, R., Paul, W. and Sharma, C.P. (2010) Development and characterization of self-aggregated nanoparticles from anacardoylated chitosan as a carrier for insulin. Carbohydr. Polym., 80, 285-290.
83. Hacein-Bey-Abina, S., von Kalle, C., Schmidt, M. et al. (2003)A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med., 348, 255-256.
84. Marshall, E. (1999) Gene therapy death prompts review of adenovirus vector. Science, 286, 2244-2245.
85. Mumper, R.J., Wang, J.J., Claspell, J.M. and Rolland, A.P. (1995) Novel polymeric condensing carriers for gene delivery. Proc. Int. Symp. Control. Rel. Bioact. Mater., 22, 178-179.
86. Weecharangsan, W., Opanasopit, P., Ngawhirunpat, T. et al. (2008) Evaluation of chitosan salts as non-viral gene vectors in CHO-K1 cells. Int. J. Pharm., 348, 161-168.
87. Erbacher, P., Zou, S., Bettinger, T. et al. (1998) Chitosan-based vector/DNAcomplexes for gene delivery: biophysical characteristics and transfection ability. Pharm. Res., 15, 1332-1339.
88. Mao, H.Q., Roy, K., Troung-Le, V.L. et al. (2001) Chitosan-DNA nanoparticles as gene carriers: synthesis, characterization and transfection efficiency. J. Control. Release, 70399-421.
89. Sato, T., Ishii, T. and Okahata, Y. (2001) In vitro gene delivery mediated by chitosan: effect of pH, serum, and molecular mass of chitosan on the transfection efficiency. Biomaterials, 22, 2075-2080.
90. Kadiyala, I., Loo,Y., Roy,K. et al. (2010)Transport of chitosan-DNAnanoparticles in human intestinal M-cell model versus normal intestinal enterocytes. Eur. J. Pharm. Sci., 39, 103-109.
91. Mansouri, S., Cuie, Y., Winnik, F. et al. (2006) Characterization of folate-chitosan-DNA nanoparticles for gene therapy. Biomaterials, 27, 2060-2065.
92. Martien, R., Loretz, B., Sandbichler, A.M. and Bernkop Schnürch, A. (2008) Thiolated chitosan nanoparticles: transfection study in the Caco-2 differentiated cell culture. Nanotechnology, 19, 045101.1-045101.9.
93. Thanou, M., Florea, B.I., Geldof, M. et al. (2002) Quaternized chitosan oligomers as novel gene delivery vectors in epithelial cell lines. Biomaterials, 23, 153-159.
94. Zheng, F., Shi, X.W., Yang, G.F. et al. (2007) Chitosan nanoparticle as gene therapy vector via gastrointestinal mucosa administration: results of an in vitro and in vivo study. Life Sci., 80, 388-396.
95. Bowman, K., Sarkar, R., Raut, S. and Leong, K.W. (2008) Gene transfer to hemophilia A mice via oral delivery of FVIII-chitosan nanoparticles. J. Control. Release, 132, 252-259.
96. Roy, K., Mao, H.Q., Huang, S.K. and Leong, K.W. (1999) Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat. Med., 5, 387-391.
97. Chew, J.L., Wolfowicz, C.B., Mao, H.Q. et al. (2003) Chitosan nanoparticles containing plasmid DNA encoding house dust mite allergen, Der p 1 for oral vaccination in mice. Vaccine, 21, 2720-2729.
98. Lorenzen, N., Lorenzen, E., Einer-Jensen, K. and LaPatra, S.E. (2002) Immunity induced shortly after DNA vaccination of rainbow trout against rhabdoviruses protects against heterologous virus but not against bacterial pathogens. Dev. Comp. Immunol., 26, 173-179.
99. Einer-Jensen, K., Delgado, L., Lorenzen, E. et al. (2009) Dual DNA vaccination of rainbow trout (Oncorhynchus mykiss) against two different rhabdoviruses, VHSV and IHNV, induces specific divalent protection. Vaccine, 27, 1248-1253.
100. Ramos, E.A., Relucio, J.L. and Torres-Villanueva, C.A. (2005) Gene expression in tilapia following oral delivery of chitosan-encapsulated plasmid DNA incorporated into fish feeds. Mar. Biotechnol., 7, 89-94.
101. Kumar, S.R., Ahmed,V.P.I., Parameswaran,V. et al. (2008) Potential use of chitosan nanoparticles for oral delivery of DNA vaccine in Asian sea bass (Lates calcarifer) to protect from Vibrio (Listonella) anguillarum. Fish Shellfish Immunol., 25, 47-56.